264 related articles for article (PubMed ID: 20181765)
1. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.
Pratt WD; Wang D; Nichols DK; Luo M; Woraratanadharm J; Dye JM; Holman DH; Dong JY
Clin Vaccine Immunol; 2010 Apr; 17(4):572-81. PubMed ID: 20181765
[TBL] [Abstract][Full Text] [Related]
2. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
3. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
[TBL] [Abstract][Full Text] [Related]
4. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
Geisbert TW; Geisbert JB; Leung A; Daddario-DiCaprio KM; Hensley LE; Grolla A; Feldmann H
J Virol; 2009 Jul; 83(14):7296-304. PubMed ID: 19386702
[TBL] [Abstract][Full Text] [Related]
5. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.
Swenson DL; Wang D; Luo M; Warfield KL; Woraratanadharm J; Holman DH; Dong JY; Pratt WD
Clin Vaccine Immunol; 2008 Mar; 15(3):460-7. PubMed ID: 18216185
[TBL] [Abstract][Full Text] [Related]
6. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
[TBL] [Abstract][Full Text] [Related]
7. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
Wong G; Richardson JS; Pillet S; Racine T; Patel A; Soule G; Ennis J; Turner J; Qiu X; Kobinger GP
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S379-83. PubMed ID: 25957963
[TBL] [Abstract][Full Text] [Related]
9. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
10. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
Front Immunol; 2021; 12():703986. PubMed ID: 34484200
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.
Hensley LE; Mulangu S; Asiedu C; Johnson J; Honko AN; Stanley D; Fabozzi G; Nichol ST; Ksiazek TG; Rollin PE; Wahl-Jensen V; Bailey M; Jahrling PB; Roederer M; Koup RA; Sullivan NJ
PLoS Pathog; 2010 May; 6(5):e1000904. PubMed ID: 20502688
[TBL] [Abstract][Full Text] [Related]
13. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.
Stanley DA; Honko AN; Asiedu C; Trefry JC; Lau-Kilby AW; Johnson JC; Hensley L; Ammendola V; Abbate A; Grazioli F; Foulds KE; Cheng C; Wang L; Donaldson MM; Colloca S; Folgori A; Roederer M; Nabel GJ; Mascola J; Nicosia A; Cortese R; Koup RA; Sullivan NJ
Nat Med; 2014 Oct; 20(10):1126-9. PubMed ID: 25194571
[TBL] [Abstract][Full Text] [Related]
14. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.
Sullivan NJ; Geisbert TW; Geisbert JB; Shedlock DJ; Xu L; Lamoreaux L; Custers JH; Popernack PM; Yang ZY; Pau MG; Roederer M; Koup RA; Goudsmit J; Jahrling PB; Nabel GJ
PLoS Med; 2006 Jun; 3(6):e177. PubMed ID: 16683867
[TBL] [Abstract][Full Text] [Related]
15. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.
Richardson JS; Yao MK; Tran KN; Croyle MA; Strong JE; Feldmann H; Kobinger GP
PLoS One; 2009; 4(4):e5308. PubMed ID: 19390586
[TBL] [Abstract][Full Text] [Related]
16. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.
Geisbert TW; Daddario-Dicaprio KM; Geisbert JB; Reed DS; Feldmann F; Grolla A; Ströher U; Fritz EA; Hensley LE; Jones SM; Feldmann H
Vaccine; 2008 Dec; 26(52):6894-900. PubMed ID: 18930776
[TBL] [Abstract][Full Text] [Related]
17. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.
Richardson JS; Pillet S; Bello AJ; Kobinger GP
J Virol; 2013 Apr; 87(7):3668-77. PubMed ID: 23302894
[TBL] [Abstract][Full Text] [Related]
18. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.
Choi JH; Jonsson-Schmunk K; Qiu X; Shedlock DJ; Strong J; Xu JX; Michie KL; Audet J; Fernando L; Myers MJ; Weiner D; Bajrovic I; Tran LQ; Wong G; Bello A; Kobinger GP; Schafer SC; Croyle MA
Mol Pharm; 2015 Aug; 12(8):2712-31. PubMed ID: 25363619
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
20. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
Wu S; Kroeker A; Wong G; He S; Hou L; Audet J; Wei H; Zhang Z; Fernando L; Soule G; Tran K; Bi S; Zhu T; Yu X; Chen W; Qiu X
J Infect Dis; 2016 Oct; 214(suppl 3):S326-S332. PubMed ID: 27493239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
